CLINICAL TRIALS PROFILE FOR INSULIN ZINC SUSP PROMPT BEEF
✉ Email this page to a colleague
All Clinical Trials for insulin zinc susp prompt beef
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00467246 ↗ | Sub-Cutaneous Insulin in Hyperglycaemic Emergencies | Withdrawn | The Royal Bournemouth Hospital | N/A | 1969-12-31 | Hyperglycaemic emergencies are associated with significant mortality (mortality in Diabetic Ketoacidosis 0.65 - 3.3% and in HyperOsmolar Non-Ketotic Coma 12 -17%). To reduce morbidity and mortality, prompt intervention and coma and close monitoring are essential. The study is designed to investigate whether a simple intervention with a long acting insulin can improve resolution of acidosis and hyperglycaemia, prevent recurrence of ketoacidosis and shorten hospital stay. |
| NCT00657280 ↗ | Study of the Effect of Sitagliptin on Glucose (Sugar) Metabolism in Patients With Heart Failure | Completed | Merck Sharp & Dohme Corp. | Early Phase 1 | 2008-04-01 | This study will investigate the effects of sitagliptin, a medicine commonly used to treat type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure which is not due to heart attacks. We hope to determine whether improving the heart's ability to use glucose in the blood may help improve the function of the heart as well. If so, this may suggest that even people who do not have frank diabetes but who do have heart failure may benefit from using this medication. This study will also investigate the effect of sitagliptin on the body's use of sugar, and of the effect of sitagliptin on blood flow to the heart. |
| NCT00657280 ↗ | Study of the Effect of Sitagliptin on Glucose (Sugar) Metabolism in Patients With Heart Failure | Completed | Stanford University | Early Phase 1 | 2008-04-01 | This study will investigate the effects of sitagliptin, a medicine commonly used to treat type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure which is not due to heart attacks. We hope to determine whether improving the heart's ability to use glucose in the blood may help improve the function of the heart as well. If so, this may suggest that even people who do not have frank diabetes but who do have heart failure may benefit from using this medication. This study will also investigate the effect of sitagliptin on the body's use of sugar, and of the effect of sitagliptin on blood flow to the heart. |
| NCT01016509 ↗ | Tight Glycemic Control During Angioplasty Revascularization Reduces Coronary Stent Restenosis | Completed | Second University of Naples | N/A | 2009-12-01 | A multicentric study will evaluate whether peri-procedural tight glycemic control during angioplasty revascularization for acute coronary syndrome (ACS) reduces circulating inflammatory cytokines and thrombus formation in hyperglycaemic patients. Moreover, the investigators will assess whether the tight glycemic control during the first month from coronary event reduces the incidence of coronary stent restenosis at 6-months from PCI. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for insulin zinc susp prompt beef
Condition Name
Clinical Trial Locations for insulin zinc susp prompt beef
Trials by Country
Clinical Trial Progress for insulin zinc susp prompt beef
Clinical Trial Phase
Clinical Trial Sponsors for insulin zinc susp prompt beef
Sponsor Name
